Plain-English translation of NCT07157969 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding interventional procedures (special minimally invasive treatments that target tumors directly in the liver) to combination immunotherapy and anti-growth medications can help people with advanced liver cancer live longer and see their tumors shrink. You would receive immune-boosting drugs like , , , , or combined with anti-growth medications like , , or —and depending on which group you're in, you may also receive interventional procedures designed to directly treat your liver tumors.
Currently, people with advanced liver cancer have limited treatment options. This trial is exploring whether combining these newer immunotherapy approaches with direct tumor-targeting procedures might work better than the medications alone to help more patients respond to treatment.
You likely qualify if…
You likely don't qualify if…
You would be assigned to one of two groups: one receiving the combination medications alone, and the other receiving the same medications plus interventional procedures performed on your liver. Your doctors will monitor you closely with regular follow-up visits, blood tests, and imaging scans to see how you're responding and to watch for any side effects. The exact number and timing of interventional procedures would be tailored to your individual condition.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China